Eikon Therapeutics, Inc. (EIKN) IPO - S-1 Filing, Stock & Insider Activity
Eikon Therapeutics, Inc. IPO - Status & S-1 Filing
- Ticker: EIKN
- Status: Priced - IPO complete
- S-1 filed: 2026-01-09
- Effective: 2026-01-30
- IPO / pricing date: 2026-02-05
- Exchange: NASDAQ
- Expected price range: $16.00–$18.00
- Shares offered: 21,177,600
- SEC CIK: 0001861123 · View the S-1 on SEC EDGAR →
Eikon Therapeutics, Inc. is pre-IPO, so no insider Form 4 transactions have been filed yet. Once insiders begin reporting trades after the offering, they will appear on this page automatically.
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
Eikon Therapeutics, Inc. (EIKN) - no SEC Form 4 insider filings recorded in the last 90 days. 4 Form 8-K material event filings were reported by EIKN in the last 90 days. InsiderAlpha tracks every EIKN SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics, Inc. trades under the ticker EIKN. InsiderAlpha tracks 13 primary SEC Form 4 filings from 11 reporting insiders for EIKN since 2026, sourced directly from SEC EDGAR.
| SEC CIK | 0001861123 |
|---|
90-Day SEC Filing Activity
| Form 8-K filings (90d) | 4 |
|---|---|
| Latest Form 4 filing | 2026-03-04 |
Recent EIKN Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Column Group IV GP, LP | Insider | J - Other acquisition / disposition | 1.40M | - | - | SEC | |
| Column Group IV GP, LP | Insider | P - Open-market purchase | 1.44M | $18.00 | $25.87M | SEC | |
| Column Group IV GP, LP | Insider | J - Other acquisition / disposition | 1.30M | - | - | SEC | |
| Josh Wolfe | Insider | J - Other acquisition / disposition | 1.15M | - | - | SEC | |
| Column Group IV GP, LP | Insider | J - Other acquisition / disposition | 44.2K | - | - | SEC | |
| Column Group IV GP, LP | Insider | J - Other acquisition / disposition | 688.3K | - | - | SEC | |
| Josh Wolfe | Insider | J - Other acquisition / disposition | 2.39M | - | - | SEC | |
| Lux Venture Partners V, LLC | Insider | J - Other acquisition / disposition | 2.39M | - | - | SEC | |
| Lux Venture Partners V, LLC | Insider | J - Other acquisition / disposition | 1.15M | - | - | SEC | |
| Lux Venture Partners V, LLC | Insider | J - Other acquisition / disposition | 2.16M | - | - | SEC | |
| Josh Wolfe | Insider | J - Other acquisition / disposition | 2.16M | - | - | SEC | |
| Column Group IV GP, LP | Insider | J - Other acquisition / disposition | 110.9K | - | - | SEC | |
| Column Group IV GP, LP | Insider | J - Other acquisition / disposition | 47.9K | - | - | SEC | |
| Column Group IV GP, LP | Insider | J - Other acquisition / disposition | 3.8K | - | - | SEC | |
| Column Group IV GP, LP | Insider | P - Open-market purchase | 49.6K | $18.00 | $892K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Eikon Therapeutics, Inc. (EIKN). Updated in real time as new filings are submitted to the SEC.
Recent EIKN Form 8-K Material Events
- - Item 5.02 [SEC]
- - Item 5.02 [SEC]
- - Item 7.01, 8.01, 9.01 [SEC]
- - Item 2.02, 7.01, 9.01 [SEC]
- - Item 2.02, 9.01 · Earnings · neutral [SEC]
Eikon Therapeutics issued a press release on March 30, 2026 announcing clinical and corporate updates along with financial results for Q4 2025 and full year 2025. The filing provides standard quarterly and annual financial reporting without explicit beat/miss or guidance language
Recent Insider Filings
- - Michael A. Klobuchar (Chief Operating Officer)
- - Robert Luther Huffines (Insider)
- - Kenneth C. Frazier (Insider)
- - Roger M. Perlmutter (Chief Executive Officer and Director)
- - Benjamin Bruno Thorner (General Counsel and Chief Business Officer)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in EIKN insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
EIKN Insider Trading - FAQ
- What is the latest insider trade for EIKN?
- Eikon Therapeutics, Inc. (EIKN) had 0 insider filings in the last 90 days, with the most recent on 2026-03-04. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying EIKN stock?
- 0 insider purchases of EIKN were filed in the last 90 days.
- How many insiders are selling EIKN stock?
- 0 insider sales of EIKN were filed in the last 90 days.
- Where can I see EIKN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks EIKN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $EJTTF easyJet plc
- $ELAB PMGC Holdings Inc.
- $ELDN Eledon Pharmaceuticals, Inc.
- $ELMT Elmet Group Co.
- $ELOX Eloxx Pharmaceuticals, Inc.
- $ELPW Elong Power Holding Ltd.
- $EMAT Evolution Metals & Technologies Corp.
- $EMI Encore Medical, Inc.
- $ENGS Energys Group Ltd
- $ENRD Einride AB
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live EIKN dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.